Business Description
Genocea Biosciences Inc
NAICS : 325412
SIC : 2834
Share Class Description:
GGNNQ: Warrants - Class A (09/01/2023)Description
Genocea Biosciences Inc is a USA-based biopharmaceutical company discovering and developing novel cancer immunotherapies using its proprietary ATLAS platform. The ATLAS platform can profile each patient's CD4+ and CD8+ T cell immune responses to every potential target or antigen identified by next-generation sequencing of that patient's tumor. ATLAS zeroes in on both antigens that activate anti-tumor T cell responses and inhibitory antigens, or Inhibigens , that drive pro-tumor immune responses.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.3 | |||||
| Equity-to-Asset | 0.32 | |||||
| Debt-to-Equity | 1.25 | |||||
| Debt-to-EBITDA | -0.45 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -18.12 | |||||
| Beneish M-Score | -3.33 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 43.7 | |||||
| 3-Year EPS without NRI Growth Rate | 43.7 | |||||
| 3-Year FCF Growth Rate | 43.9 | |||||
| 3-Year Book Growth Rate | -8.7 |
Momentum Rank
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.35 | |||||
| Quick Ratio | 1.35 | |||||
| Cash Ratio | 1.12 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -75.1 | |||||
| Shareholder Yield % | 5.61 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -2901.31 | |||||
| Net Margin % | -1946.15 | |||||
| ROE % | -223.76 | |||||
| ROA % | -57.93 | |||||
| ROIC % | -241.51 | |||||
| ROC (Joel Greenblatt) % | -267.75 | |||||
| ROCE % | -74.22 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | 0.13 | |||||
| EV-to-EBITDA | 0.13 | |||||
| EV-to-Revenue | -2.43 | |||||
| EV-to-FCF | 0.09 | |||||
| Earnings Yield (Greenblatt) % | 769.23 | |||||
| FCF Yield % | -855433.33 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:GGNNQ
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Genocea Biosciences Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | 0 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR ($) | 0 | ||
| 20-Day SMA ($) | 0 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range ($) | 0 - 0.21 | ||
| Shares Outstanding (Mil) |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Genocea Biosciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Genocea Biosciences Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Genocea Biosciences Inc Frequently Asked Questions
What is Genocea Biosciences Inc(GGNNQ)'s stock price today?
The current price of GGNNQ is $0.00. The 52 week high of GGNNQ is $0.21 and 52 week low is $0.00.
When is next earnings date of Genocea Biosciences Inc(GGNNQ)?
The next earnings date of Genocea Biosciences Inc(GGNNQ) is 2024-11-29 Est..
Does Genocea Biosciences Inc(GGNNQ) pay dividends? If so, how much?
Genocea Biosciences Inc(GGNNQ) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers